Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (101-110 of 440) with videos related to

Pageof 44
Sort By:
Current Problems in Cancer|June 5, 2007
Racial differences in the incidence and outcomes for patients with hematological malignanciesChristopher R Flowers, Roni Glover, Sagar Lonial, et al.
Clinical Pharmacology : Advances and Applications|August 26, 2021
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and SelinexorNisha S Joseph, Yu-Tzu Tai, Kenneth C Anderson, et al.
Cancer Biology & Therapy|September 26, 2003
Signal transduction and myeloma: new targets, new hopeSagar Lonial, Edmund K Waller, Jonathan W Simons, et al.
Experimental Hematology|November 22, 2011
Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsinCynthia R Giver, David L Jaye, Edmund K Waller, et al.
Blood Advances|January 4, 2018
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myelomaShardule P Shah, Ajay K Nooka, Sagar Lonial, et al.
Molecular Cancer Therapeutics|September 15, 2011
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cellsLiqun Zhao, Ping Yue, Sagar Lonial, et al.
Future Oncology (London, England)|August 24, 2018
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myelomaSarah Chehab, Elyse Hall Panjic, Charise Gleason, et al.
Blood Advances|January 9, 2024
Shrinking the divide: improving myeloma CART accessAjay K Nooka, Monique A Hartley-Brown, Kenneth C Anderson, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 21, 2019
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging AgentsDeepu Madduri, Madhav V Dhodapkar, Sagar Lonial, et al.
Cancer|March 29, 2019
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studiesR Donald Harvey, Chao Zhang, Sagar Lonial, et al.
Pageof 44

Showing results (101-110 of 440) with videos related to

Sort By:
Pageof 44
Current Problems in Cancer|June 5, 2007
Racial differences in the incidence and outcomes for patients with hematological malignanciesChristopher R Flowers, Roni Glover, Sagar Lonial, et al.
Clinical Pharmacology : Advances and Applications|August 26, 2021
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and SelinexorNisha S Joseph, Yu-Tzu Tai, Kenneth C Anderson, et al.
Cancer Biology & Therapy|September 26, 2003
Signal transduction and myeloma: new targets, new hopeSagar Lonial, Edmund K Waller, Jonathan W Simons, et al.
Experimental Hematology|November 22, 2011
Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsinCynthia R Giver, David L Jaye, Edmund K Waller, et al.
Blood Advances|January 4, 2018
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myelomaShardule P Shah, Ajay K Nooka, Sagar Lonial, et al.
Molecular Cancer Therapeutics|September 15, 2011
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cellsLiqun Zhao, Ping Yue, Sagar Lonial, et al.
Future Oncology (London, England)|August 24, 2018
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myelomaSarah Chehab, Elyse Hall Panjic, Charise Gleason, et al.
Blood Advances|January 9, 2024
Shrinking the divide: improving myeloma CART accessAjay K Nooka, Monique A Hartley-Brown, Kenneth C Anderson, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 21, 2019
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging AgentsDeepu Madduri, Madhav V Dhodapkar, Sagar Lonial, et al.
Cancer|March 29, 2019
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studiesR Donald Harvey, Chao Zhang, Sagar Lonial, et al.
Pageof 44